Buprenorphine decreases the CCL2-mediated chemotactic response of monocytes

Journal of Immunology

Volumn 194, Issue 7, 2015, Pages 3246-3258

  Carvallo, Loreto ^a   Lopez, Lillie ^a   Che, Fa Yun ^a   Lim, Jihyeon ^a   Eugenin, Eliseo A ^b,c   Williams, Dionna W ^a   Nieves, Edward ^a   Calderon, Tina M ^a   Madrid Aliste, Carlos ^a   Fiser, Andras ^a   Weiss, Louis ^a   Angeletti, Ruth Hogue ^a   Berman, Joan W ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; CALGRANULIN B; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLARGINYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; LEUKOSIALIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NORBINALTORPHIMINE; CELL ADHESION MOLECULE; CELL SURFACE RECEPTOR; CHEMOKINE RECEPTOR CCR2; F11R PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE P38; NARCOTIC ANALGESIC AGENT; OPIATE RECEPTOR; PHOSPHOPEPTIDE; PROTEOME;

ARTICLE; CHEMOTAXIS; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; MONOCYTE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEOMICS; SIGNAL TRANSDUCTION; CELL MEMBRANE; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; NEUTROPHIL CHEMOTAXIS; PHENOTYPE; PHOSPHORYLATION;

ANALGESICS, OPIOID; BUPRENORPHINE; CELL ADHESION MOLECULES; CELL MEMBRANE; CHEMOKINE CCL2; CHEMOTAXIS, LEUKOCYTE; HUMANS; MONOCYTES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHENOTYPE; PHOSPHOPEPTIDES; PHOSPHORYLATION; PROTEOME; PROTEOMICS; RECEPTORS, CCR2; RECEPTORS, CELL SURFACE; RECEPTORS, OPIOID;

EID: 84925862733     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302647     Document Type: Article

References (102)

1. UNAIDS. UNAIDS World AIDS Day Report. Available at: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/jc2216-worldaidsday-report-2011-en.pdf
2. Davis, L. E., B. L. Hjelle, V. E. Miller, D. L. Palmer, A. L. Llewellyn, T. L. Merlin, S. A. Young, R. G. Mills, W. Wachsman, and C. A. Wiley. 1992. Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology 42: 1736-1739.
3. Ances, B. M., and R. J. Ellis. 2007. Dementia and neurocognitive disorders due to HIV-1 infection. Semin. Neurol. 27: 86-92.
4. Rackstraw, S. 2011. HIV-related neurocognitive impairment - a review. Psychol. Health Med. 16: 548-563.
5. Woods, S. P., D. J. Moore, E. Weber, and I. Grant. 2009. Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol. Rev. 19: 152-168.
6. Cysique, L. A., F. Vaida, S. Letendre, S. Gibson, M. Cherner, S. P. Woods, J. A. McCutchan, R. K. Heaton, and R. J. Ellis. 2009. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 73: 342-348.
7. Wu, D. T., S. E. Woodman, J. M. Weiss, C. M. McManus, T. G. D'Aversa, J. Hesselgesser, E. O. Major, A. Nath, and J. W. Berman. 2000. Mechanisms of leukocyte trafficking into the CNS. J. Neurovirol. 6(Suppl. 1): S82-S85.
8. Kanmogne, G. D., K. Schall, J. Leibhart, B. Knipe, H. E. Gendelman, and Y. Persidsky. 2007. HIV-1 gp120 compromises blood-brain barrier integrity and enhances monocyte migration across blood-brain barrier: implication for viral neuropathogenesis. J. Cereb. Blood Flow Metab. 27: 123-134.
9. Nath, A., K. Conant, P. Chen, C. Scott, and E. O. Major. 1999. Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes: a hit and run phenomenon. J. Biol. Chem. 274: 17098-17102.
10. Zhang, K., G. A. McQuibban, C. Silva, G. S. Butler, J. B. Johnston, J. Holden, I. Clark-Lewis, C. M. Overall, and C. Power. 2003. HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration. Nat. Neurosci. 6: 1064-1071.
11. Koenig, S., H. E. Gendelman, J. M. Orenstein, M. C. Dal Canto, G. H. Pezeshkpour, M. Yungbluth, F. Janotta, A. Aksamit, M. A. Martin, and A. S. Fauci. 1986. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 233: 1089-1093.
12. Gras, G., and M. Kaul. 2010. Molecular mechanisms of neuroinvasion by monocytes-macrophages in HIV-1 infection. Retrovirology 7: 30.
13. Yadav, A., and R. G. Collman. 2009. CNS inflammation and macrophage/microglial biology associated with HIV-1 infection. J. Neuroimmune Pharmacol. 4: 430-447.
14. Lu, B., B. J. Rutledge, L. Gu, J. Fiorillo, N. W. Lukacs, S. L. Kunkel, R. North, C. Gerard, and B. J. Rollins. 1998. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J. Exp. Med. 187: 601-608.
15. Uguccioni, M., M. D'Apuzzo, M. Loetscher, B. Dewald, and M. Baggiolini. 1995. Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 alpha and MIP-1 beta on human monocytes. Eur. J. Immunol. 25: 64-68.
16. Yuan, L., L. Qiao, F. Wei, J. Yin, L. Liu, Y. Ji, D. Smith, N. Li, and D. Chen. 2013. Cytokines in CSF correlate with HIV-associated neurocognitive disorders in the post-HAART era in China. J. Neurovirol. 19: 144-149.
17. Harezlak, J., S. Buchthal, M. Taylor, G. Schifitto, J. Zhong, E. Daar, J. Alger, E. Singer, T. Campbell, C. Yiannoutsos, et al; HIV Neuroimaging Consortium. 2011. Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS 25: 625-633.
18. Edén, A., R. W. Price, S. Spudich, D. Fuchs, L. Hagberg, and M. Gisslén. 2007. Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J. Infect. Dis. 196: 1779-1783.
19. Schouten, J., P. Cinque, M. Gisslen, P. Reiss, and P. Portegies. 2011. HIV-1 infection and cognitive impairment in the cART era: a review. AIDS 25: 561-575.
20. Kamat, A., J. L. Lyons, V. Misra, H. Uno, S. Morgello, E. J. Singer, and D. Gabuzda. 2012. Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection. J. Acquir. Immune Defic. Syndr. 60: 234-243.
21. Weiss, J. M., S. A. Downie, W. D. Lyman, and J. W. Berman. 1998. Astrocyte-derived monocyte-chemoattractant protein-1 directs the transmigration of leukocytes across a model of the human blood-brain barrier. J. Immunol. 161: 6896-6903.
22. Eugenin, E. A., K. Osiecki, L. Lopez, H. Goldstein, T. M. Calderon, and J. W. Berman. 2006. CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV)-infected leukocytes across the blood-brain barrier: a potential mechanism of HIV-CNS invasion and NeuroAIDS. J. Neurosci. 26: 1098-1106.
23. Williams, D. W., E. A. Eugenin, T. M. Calderon, and J. W. Berman. 2012. Monocyte maturation, HIV susceptibility, and transmigration across the blood brain barrier are critical in HIV neuropathogenesis. J. Leukoc. Biol. 91: 401-415.
24. Roberts, T. K., E. A. Eugenin, L. Lopez, I. A. Romero, B. B. Weksler, P. O. Couraud, and J. W. Berman. 2012. CCL2 disrupts the adherens junction: implications for neuroinflammation. Lab. Invest. 92: 1213-1233.
25. Hauser, K. F., N. El-Hage, S. Buch, A. Nath, W. R. Tyor, A. J. Bruce-Keller, and P. E. Knapp. 2006. Impact of opiate-HIV-1 interactions on neurotoxic signaling. J. Neuroimmune Pharmacol. 1: 98-105.
26. Donahoe, R. M., and D. Vlahov. 1998. Opiates as potential cofactors in progression of HIV-1 infections to AIDS. J. Neuroimmunol. 83: 77-87.
27. Anthony, I. C., D. H. Crawford, and J. E. Bell. 2004. Effects of human immunodeficiency virus encephalitis and drug abuse on the B lymphocyte population of the brain. J. Neurovirol. 10: 181-188.
28. Gowing, L., R. Ali, and J. M. White. 2009. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst. Rev. 3:CD002025.
29. Rapeli, P., C. Fabritius, H. Kalska, and H. Alho. 2011. Cognitive functioning in opioid-dependent patients treated with buprenorphine, methadone, and other psychoactive medications: stability and correlates. BMC Clin. Pharmacol. 11: 13.
30. Pirastu, R., R. Fais, M. Messina, V. Bini, S. Spiga, D. Falconieri, and M. Diana. 2006. Impaired decision-making in opiate-dependent subjects: effect of pharmacological therapies. Drug Alcohol Depend. 83: 163-168.
31. Sung, S., and J. M. Conry. 2006. Role of buprenorphine in the management of heroin addiction. Ann. Pharmacother. 40: 501-505.
32. Grimm, M. C., A. Ben-Baruch, D. D. Taub, O. M. Howard, J. H. Resau, J. M. Wang, H. Ali, R. Richardson, R. Snyderman, and J. J. Oppenheim. 1998. Opiates transdeactivate chemokine receptors: delta and mu opiate receptor-mediated heterologous desensitization. J. Exp. Med. 188: 317-325.
33. Miyagi, T., L. F. Chuang, K. M. Lam, H. Kung, J. M. Wang, B. I. Osburn, and R. Y. Chuang. 2000. Opioids suppress chemokine-mediated migration of monkey neutrophils and monocytes: an instant response. Immunopharmacology 47: 53-62.
34. Pérez-Castrillón, J. L., J. L. Pérez-Arellano, J. D. García-Palomo, A. Jiménez-López, and S. De Castro. 1992. Opioids depress in vitro human monocyte chemotaxis. Immunopharmacology 23: 57-61.
35. Salentin, R., D. Gemsa, H. Sprenger, and A. Kaufmann. 2003. Chemokine receptor expression and chemotactic responsiveness of human monocytes after influenza A virus infection. J. Leukoc. Biol. 74: 252-259.
36. Wetzel, M. A., A. D. Steele, T. K. Eisenstein, M. W. Adler, E. E. Henderson, and T. J. Rogers. 2000. Mu-opioid induction of monocyte chemoattractant protein-1, RANTES, and IFN-gamma-inducible protein-10 expression in human peripheral blood mononuclear cells. J. Immunol. 165: 6519-6524.
37. Finley, M. J., A. Steele, W. D. Cornwell, and T. J. Rogers. 2011. Transcriptional regulation of the major HIV-1 coreceptor, CXCR4, by the kappa opioid receptor. J. Leukoc. Biol. 90: 111-121.
38. Shen, H., A. Aeschlimann, N. Reisch, R. E. Gay, B. R. Simmen, B. A. Michel, S. Gay, and H. Sprott. 2005. Kappa and delta opioid receptors are expressed but down-regulated in fibroblast-like synoviocytes of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum. 52: 1402-1410.
39. Patel, J. P., R. Sengupta, G. Bardi, M. Z. Khan, A. Mullen-Przeworski, and O. Meucci. 2006. Modulation of neuronal CXCR4 by the micro-opioid agonist DAMGO. J. Neurovirol. 12: 492-500.
40. Steele, A. D., E. E. Henderson, and T. J. Rogers. 2003. Mu-opioid modulation of HIV-1 coreceptor expression and HIV-1 replication. Virology 309: 99-107.
41. Lim, J., V. Menon, M. Bitzer, L. M. Miller, C. Madrid-Aliste, L. M. Weiss, A. Fiser, and R. H. Angeletti. 2011. Frozen tissue can provide reproducible proteomic results of subcellular fractionation. Anal. Biochem. 418: 78-84.
42. Fleitz, A., E. Nieves, C. Madrid-Aliste, S. J. Fentress, L. D. Sibley, L. M. Weiss, R. H. Angeletti, and F. Y. Che. 2013. Enhanced detection of multiply phosphorylated peptides and identification of their sites of modification. Anal. Chem. 85: 8566-8576.
43. Mitchison, T. J., and L. P. Cramer. 1996. Actin-based cell motility and cell locomotion. Cell 84: 371-379.
44. Burridge, K., and M. Chrzanowska-Wodnicka. 1996. Focal adhesions, contractility, and signaling. Annu. Rev. Cell Dev. Biol. 12: 463-518.
45. Pollard, T. D., and J. A. Cooper. 2009. Actin, a central player in cell shape and movement. Science 326: 1208-1212.
46. Lopker, A., L. G. Abood, W. Hoss, and F. J. Lionetti. 1980. Stereoselective muscarinic acetylcholine and opiate receptiors in human phagocytic leukocytes. Biochem. Pharmacol. 29: 1361-1365.
47. Gavériaux, C., J. Peluso, F. Simonin, J. Laforet, and B. Kieffer. 1995. Identification of kappa- and delta-opioid receptor transcripts in immune cells. FEBS Lett. 369: 272-276.
48. Cadet, P., K. Mantione, T. V. Bilfinger, and G. B. Stefano. 2001. Real-time RT-PCR measurement of the modulation of Mu opiate receptor expression by nitric oxide in human mononuclear cells. Med. Sci. Monit. 7: 1123-1128.
49. Chuang, T. K., K. F. Killam, Jr., L. F. Chuang, H. F. Kung, W. S. Sheng, C. C. Chao, L. Yu, and R. Y. Chuang. 1995. Mu opioid receptor gene expression in immune cells. Biochem. Biophys. Res. Commun. 216: 922-930.
50. Walsh, S. L., K. L. Preston, M. L. Stitzer, E. J. Cone, and G. E. Bigelow. 1994. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin. Pharmacol. Ther. 55: 569-580.
51. Schuh, K. J., and C. E. Johanson. 1999. Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet. Drug Alcohol Depend. 56: 55-60.
52. McCance-Katz, E. F., D. E. Moody, G. D. Morse, Q. Ma, R. DiFrancesco, G. Friedland, P. Pade, and P. M. Rainey. 2007. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend. 91: 269-278.
53. Lind, M., M. C. Trindade, Y. Nakashima, D. J. Schurman, S. B. Goodman, and L. Smith. 1999. Chemotaxis and activation of particle-challenged human monocytes in response to monocyte migration inhibitory factor and C-C chemokines. J. Biomed. Mater. Res. 48: 246-250.
54. Ubogu, E. E., M. B. Cossoy, and R. M. Ransohoff. 2006. The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol. Sci. 27: 48-55.
55. Rollins, B. J. 1996. Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. Mol. Med. Today 2: 198-204.
56. Volpe, S., E. Cameroni, B. Moepps, S. Thelen, T. Apuzzo, and M. Thelen. 2012. CCR2 acts as scavenger for CCL2 during monocyte chemotaxis. PLoS One 7: e37208.
57. Neel, N. F., E. Schutyser, J. Sai, G. H. Fan, and A. Richmond. 2005. Chemokine receptor internalization and intracellular trafficking. Cytokine Growth Factor Rev. 16: 637-658.
58. Borroni, E. M., A. Mantovani, M. Locati, and R. Bonecchi. 2010. Chemokine receptors intracellular trafficking. Pharmacol. Ther. 127: 1-8.
59. García Lopez, M. A., A. Aguado Martínez, C. Lamaze, C. Martínez-A, and T. Fischer. 2009. Inhibition of dynamin prevents CCL2-mediated endocytosis of CCR2 and activation of ERK1/2. Cell. Signal. 21: 1748-1757.
60. Berchiche, Y. A., S. Gravel, M. E. Pelletier, G. St-Onge, and N. Heveker. 2011. Different effects of the different natural CC chemokine receptor 2b ligands on beta-arrestin recruitment, Gαi signaling, and receptor internalization. Mol. Pharmacol. 79: 488-498.
61. Handel, T. M., Z. Johnson, D. H. Rodrigues, A. C. Dos Santos, R. Cirillo, V. Muzio, S. Riva, M. Mack, M. Déruaz, F. Borlat, et al. 2008. An engineered monomer of CCL2 has anti-inflammatory properties emphasizing the importance of oligomerization for chemokine activity in vivo. J. Leukoc. Biol. 84: 1101-1108.
62. Sharma, G. D., J. He, and H. E. Bazan. 2003. p38 and ERK1/2 coordinate cellular migration and proliferation in epithelial wound healing: evidence of cross-talk activation between MAP kinase cascades. J. Biol. Chem. 278: 21989-21997.
63. Zhuang, S., Y. Dang, and R. G. Schnellmann. 2004. Requirement of the epidermal growth factor receptor in renal epithelial cell proliferation and migration. Am. J. Physiol. Renal Physiol. 287: F365-F372.
64. Ashida, N., H. Arai, M. Yamasaki, and T. Kita. 2001. Distinct signaling pathways for MCP-1-dependent integrin activation and chemotaxis. J. Biol. Chem. 276: 16555-16560.
65. Ayala, J. M., S. Goyal, N. J. Liverton, D. A. Claremon, S. J. O'Keefe, and W. A. Hanlon. 2000. Serum-induced monocyte differentiation and monocyte chemotaxis are regulated by the p38 MAP kinase signal transduction pathway. J. Leukoc. Biol. 67: 869-875.
66. Cambien, B., M. Pomeranz, M. A. Millet, B. Rossi, and A. Schmid-Alliana. 2001. Signal transduction involved in MCP-1-mediated monocytic transendothelial migration. Blood 97: 359-366.
67. Williams, D. W., T. M. Calderon, L. Lopez, L. Carvallo-Torres, P. J. Gaskill, E. A. Eugenin, S. Morgello, and J. W. Berman. 2013. Mechanisms of HIV entry into the CNS: increased sensitivity of HIV infected CD14+CD16+ monocytes to CCL2 and key roles of CCR2, JAM-A, and ALCAM in diapedesis. PLoS One 8: e69270.
68. Del Maschio, A., A. De Luigi, I. Martin-Padura, M. Brockhaus, T. Bartfai, P. Fruscella, L. Adorini, G. Martino, R. Furlan, M. G. De Simoni, and E. Dejana. 1999. Leukocyte recruitment in the cerebrospinal fluid of mice with experimental meningitis is inhibited by an antibody to junctional adhesion molecule (JAM). J. Exp. Med. 190: 1351-1356.
69. Martìn-Padura, I., S. Lostaglio, M. Schneemann, L. Williams, M. Romano, P. Fruscella, C. Panzeri, A. Stoppacciaro, L. Ruco, A. Villa, et al. 1998. Junctional adhesion molecule, a novel member of the immunoglobulin super-family that distributes at intercellular junctions and modulates monocyte transmigration. J. Cell Biol. 142: 117-127.
70. Mandell, K. J., and C. A. Parkos. 2005. The JAM family of proteins. Adv. Drug Deliv. Rev. 57: 857-867.
71. Williams, L. A., I. Martin-Padura, E. Dejana, N. Hogg, and D. L. Simmons. 1999. Identification and characterisation of human junctional adhesion molecule (JAM). Mol. Immunol. 36: 1175-1188.
72. Roberts, T. K., C. M. Buckner, and J. W. Berman. 2010. Leukocyte transmigration across the blood-brain barrier: perspectives on neuroAIDS. Front. Biosci. (Landmark Ed.) 15: 478-536.
73. Lu, T. T., M. Barreuther, S. Davis, and J. A. Madri. 1997. Platelet endothelial cell adhesion molecule-1 is phosphorylatable by c-Src, binds Src-Src homology 2 domain, and exhibits immunoreceptor tyrosine-based activation motif-like properties. J. Biol. Chem. 272: 14442-14446.
74. Dasgupta, B., E. Dufour, Z. Mamdouh, and W. A. Muller. 2009. A novel and critical role for tyrosine 663 in platelet endothelial cell adhesion molecule-1 trafficking and transendothelial migration. J. Immunol. 182: 5041-5051.
75. Ozaki, H., K. Ishii, H. Arai, H. Horiuchi, T. Kawamoto, H. Suzuki, and T. Kita. 2000. Junctional adhesion molecule (JAM) is phosphorylated by protein kinase C upon platelet activation. Biochem. Biophys. Res. Commun. 276: 873-878.
76. Nacken, W., J. Roth, C. Sorg, and C. Kerkhoff. 2003. S100A9/S100A8: myeloid representatives of the S100 protein family as prominent players in innate immunity. Microsc. Res. Tech. 60: 569-580.
77. Edgeworth, J., M. Gorman, R. Bennett, P. Freemont, and N. Hogg. 1991. Identification of p8,14 as a highly abundant heterodimeric calcium binding protein complex of myeloid cells. J. Biol. Chem. 266: 7706-7713.
78. Rammes, A., J. Roth, M. Goebeler, M. Klempt, M. Hartmann, and C. Sorg. 1997. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J. Biol. Chem. 272: 9496-9502.
79. Roth, J., F. Burwinkel, C. van den Bos, M. Goebeler, E. Vollmer, and C. Sorg. 1993. MRP8 and MRP14, S-100-like proteins associated with myeloid differentiation, are translocated to plasma membrane and intermediate filaments in a calcium-dependent manner. Blood 82: 1875-1883.
80. Piller, V., F. Piller, and M. Fukuda. 1989. Phosphorylation of the major leukocyte surface sialoglycoprotein, leukosialin, is increased by phorbol 12-myristate 13-acetate. J. Biol. Chem. 264: 18824-18831.
81. Mody, P. D., J. L. Cannon, H. S. Bandukwala, K. M. Blaine, A. B. Schilling, K. Swier, and A. I. Sperling. 2007. Signaling through CD43 regulates CD4 T-cell trafficking. Blood 110: 2974-2982.
82. Cannon, J. L., P. D. Mody, K. M. Blaine, E. J. Chen, A. D. Nelson, L. J. Sayles, T. V. Moore, B. S. Clay, N. O. Dulin, R. A. Shilling, et al. 2011. CD43 interaction with ezrin-radixin-moesin (ERM) proteins regulates T-cell trafficking and CD43 phosphorylation. Mol. Biol. Cell 22: 954-963.
83. Matsuo, A., D. G. Walker, K. Terai, and P. L. McGeer. 1996. Expression of CD43 in human microglia and its downregulation in Alzheimer's disease. J. Neuroimmunol. 71: 81-86.
84. Peluso, R., A. Haase, L. Stowring, M. Edwards, and P. Ventura. 1985. A Trojan horse mechanism for the spread of visna virus in monocytes. Virology 147: 231-236.
85. Kim, W. K., S. Corey, X. Alvarez, and K. Williams. 2003. Monocyte/macrophage traffic in HIV and SIV encephalitis. J. Leukoc. Biol. 74: 650-656.
86. González-Scarano, F., and J. Martín-García. 2005. The neuropathogenesis of AIDS. Nat. Rev. Immunol. 5: 69-81.
87. Strathdee, S. A., and J. K. Stockman. 2010. Epidemiology of HIV among injecting and non-injecting drug users: current trends and implications for interventions. Curr. HIV/AIDS Rep. 7: 99-106.
88. Nath, A., K. F. Hauser, V. Wojna, R. M. Booze, W. Maragos, M. Prendergast, W. Cass, and J. T. Turchan. 2002. Molecular basis for interactions of HIV and drugs of abuse. J. Acquir. Immune Defic. Syndr. 31(Suppl. 2): S62-S69.
89. Meade, C. S., N. A. Conn, L. M. Skalski, and S. A. Safren. 2011. Neurocognitive impairment and medication adherence in HIV patients with and without cocaine dependence. J. Behav. Med. 34: 128-138.
90. Meade, C. S., S. B. Lowen, R. R. MacLean, M. D. Key, and S. E. Lukas. 2011. fMRI brain activation during a delay discounting task in HIV-positive adults with and without cocaine dependence. Psychiatry Res. 192: 167-175.
91. Seifert, J., C. Metzner, W. Paetzold, M. Borsutzky, T. Passie, J. Rollnik, B. Wiese, H. M. Emrich, and U. Schneider. 2002. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone. Pharmacopsychiatry 35: 159-164.
92. Walsh, S. L., and T. Eissenberg. 2003. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend. 70: S13-S27.
93. Walsh, S. L., H. L. June, K. J. Schuh, K. L. Preston, G. E. Bigelow, and M. L. Stitzer. 1995. Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology 119: 268-276.
94. McCance-Katz, E. F., L. E. Sullivan, and S. Nallani. 2010. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am. J. Addict. 19: 4-16.
95. Roux, P. P., and J. Blenis. 2004. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol. Mol. Biol. Rev. 68: 320-344.
96. Ono, K., and J. Han. 2000. The p38 signal transduction pathway: activation and function. Cell. Signal. 12: 1-13.
97. Naik, M. U., and U. P. Naik. 2006. Junctional adhesion molecule-A-induced endothelial cell migration on vitronectin is integrin alpha v beta 3 specific. J. Cell Sci. 119: 490-499.
98. Axelsson, B., and P. Perlmann. 1989. Persistent superphosphorylation of leukosialin (CD43) in activated T cells and in tumour cell lines. Scand. J. Immunol. 30: 539-547.
99. Carlsson, S. R., H. Sasaki, and M. Fukuda. 1986. Structural variations of O-linked oligosaccharides present in leukosialin isolated from erythroid, myeloid, and T-lymphoid cell lines. J. Biol. Chem. 261: 12787-12795.
100. Lominadze, G., M. J. Rane, M. Merchant, J. Cai, R. A. Ward, and K. R. McLeish. 2005. Myeloid-related protein-14 is a p38 MAPK substrate in human neutrophils. J. Immunol. 174: 7257-7267.
101. Edgeworth, J., P. Freemont, and N. Hogg. 1989. Ionomycin-regulated phosphorylation of the myeloid calcium-binding protein p14. Nature 342: 189-192.
102. van den Bos, C., J. Roth, H. G. Koch, M. Hartmann, and C. Sorg. 1996. Phosphorylation of MRP14, an S100 protein expressed during monocytic differentiation, modulates Ca(2+)-dependent translocation from cytoplasm to membranes and cytoskeleton. J. Immunol. 156: 1247-1254.